ACRV vs. PRLD, TRVI, QURE, ZVRA, DSGN, VERU, MACK, GTHX, ELYM, and TELO
Should you be buying Acrivon Therapeutics stock or one of its competitors? The main competitors of Acrivon Therapeutics include Prelude Therapeutics (PRLD), Trevi Therapeutics (TRVI), uniQure (QURE), Zevra Therapeutics (ZVRA), Design Therapeutics (DSGN), Veru (VERU), Merrimack Pharmaceuticals (MACK), G1 Therapeutics (GTHX), Eliem Therapeutics (ELYM), and Telomir Pharmaceuticals (TELO). These companies are all part of the "pharmaceutical preparations" industry.
Prelude Therapeutics (NASDAQ:PRLD) and Acrivon Therapeutics (NASDAQ:ACRV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
79.7% of Prelude Therapeutics shares are held by institutional investors. Comparatively, 71.6% of Acrivon Therapeutics shares are held by institutional investors. 79.5% of Prelude Therapeutics shares are held by insiders. Comparatively, 7.3% of Acrivon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Prelude Therapeutics had 4 more articles in the media than Acrivon Therapeutics. MarketBeat recorded 7 mentions for Prelude Therapeutics and 3 mentions for Acrivon Therapeutics. Prelude Therapeutics' average media sentiment score of 1.19 beat Acrivon Therapeutics' score of 0.47 indicating that Acrivon Therapeutics is being referred to more favorably in the news media.
Prelude Therapeutics received 2 more outperform votes than Acrivon Therapeutics when rated by MarketBeat users. However, 95.83% of users gave Acrivon Therapeutics an outperform vote while only 48.08% of users gave Prelude Therapeutics an outperform vote.
Acrivon Therapeutics is trading at a lower price-to-earnings ratio than Prelude Therapeutics, indicating that it is currently the more affordable of the two stocks.
Prelude Therapeutics presently has a consensus target price of $5.25, indicating a potential upside of 40.75%. Acrivon Therapeutics has a consensus target price of $22.63, indicating a potential upside of 157.98%. Given Prelude Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Acrivon Therapeutics is more favorable than Prelude Therapeutics.
Prelude Therapeutics' return on equity of -42.45% beat Acrivon Therapeutics' return on equity.
Prelude Therapeutics has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, Acrivon Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500.
Summary
Acrivon Therapeutics beats Prelude Therapeutics on 8 of the 15 factors compared between the two stocks.
Get Acrivon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acrivon Therapeutics Competitors List
Related Companies and Tools
